UTHR Director Reports Gifting 450 Shares of Common Stock
UNITED THERAPEUTICS Corp
Subscribe to track UTHR
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
UTHR Director Reports Gifting 450 Shares
Company: UNITED THERAPEUTICS Corp (UTHR) Form: 4 | Filed: 2025-11-04 Significance: Low
Insider: CAUSEY CHRISTOPHER Title: Not Specified | Relationship: Director
Transaction: • Type: Gift • Shares: 450 • Price: $0.00 • Value: $0 • Owned After: 4,190
Key Insight: A director gifted a small number of shares, representing a negligible 0.001% of shares outstanding. This is a routine, non-market transaction with minimal impact.
Market Context: This is a standard disclosure of a personal gift and does not signal a change in the insider's view of the company's prospects.
Comprehensive Analysis
SEC Filing Analysis: UNITED THERAPEUTICS Corp (UTHR)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director made a small gift of 450 shares, a routine non-market transaction with no material impact on the company or its stock.
- Market Impact: Neutral. This type of filing is informational and does not typically influence market activity.
Company Information
| Field | Value |
|---|---|
| Company | UNITED THERAPEUTICS Corp |
| Ticker Symbol | UTHR |
| CIK | 0001082554 |
| Industry | PHARMACEUTICAL PREPARATIONS |
Insider Information
| Field | Value |
|---|---|
| Name | CAUSEY CHRISTOPHER |
| CIK | 0001237334 |
| Title/Position | Not Specified |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-03 |
| Transaction Code | G (Gift) |
| Security Type | Common Stock |
| Shares Involved | 450 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 4,190 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.00% |
| Shares Transacted | 450 |
| % of Shares Outstanding | 0.001% |
| Post-Transaction Ownership | 4,190 shares (0.009% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The transaction involves a negligible number of shares relative to United Therapeutics' $19.18 billion market capitalization.
- Ownership Concentration: The director's post-transaction ownership of 4,190 shares is a very small fraction (0.009%) of the total shares outstanding, indicating low ownership concentration from this individual.
- Transaction Significance: The transaction is classified as a gift (Code 'G') and involved zero financial consideration. Its size relative to both market cap and shares outstanding is well below any threshold for significance.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing reports a gift, which is a non-market event. It does not reflect an insider's market sentiment or trading decision.
Volume & Sentiment
- Expected Volume Impact: None. This type of filing does not drive trading volume.
- Sentiment Indicator: Neutral. The event is a personal financial transfer, not a bullish or bearish signal.
Additional Context
Transaction Notes
- Special Circumstances: The transaction was a bona fide gift, as indicated by the 'G' transaction code and the $0.00 price per share.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.